
Nuvation Bio (NUVB) Stock Forecast & Price Target
Nuvation Bio (NUVB) Analyst Ratings
Bulls say
Nuvation Bio is well positioned to capitalize on its diverse clinical pipeline, particularly with its lead candidate, taletrectinib, showing strong promise in the treatment of ROS1+ non-small cell lung cancer. With multiple product candidates in different stages of development and a strong cash position, management has the resources to continue expanding its pipeline. In addition, the company's recent acquisition of Japan rights to safusidenib could significantly expand its market potential and contribute to future revenue growth. Overall, Nuvation Bio's differentiated approach to addressing unmet needs in oncology makes it a compelling investment opportunity.
Bears say
Nuvation Bio is a speculative investment given its dependence on the success of its first commercial launch, Ibtrozi, for revenue and the potential for positive safety and efficacy differentiators. The company's potential upside lies in its pipeline, but its near-term commercialization risk is a major factor in maintaining a "Speculative Risk" rating.
This aggregate rating is based on analysts' research of Nuvation Bio and is not a guaranteed prediction by Public.com or investment advice.
Nuvation Bio (NUVB) Analyst Forecast & Price Prediction
Start investing in Nuvation Bio (NUVB)
Order type
Buy in
Order amount
Est. shares
0 shares